Groupe d'Etude en Oncologie du Quebec

Titre	The Role of Androgen Deprivation Therapy In Cardiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1) & A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)
Protocole ID	RADICALPC
ClinicalTrials.gov ID	NCT03127631
Type(s) de cancer	Prostate
Phase	Autres
Institution	CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS 3755 rue de la Côte Ste. Catherine, Montréal, QC, H3T 1E2
Ville	Montréal
Investigateur(trice) principal(e)	Dr Tamim Niazi
Coordonnateur(trice)	Kelli Dimayuga 514-340-8222 poste 21285
Statut	Actif en recrutement
Critètes d'éligibilité	A man with a diagnosis of prostate cancer that is either: new (i.e. the diagnosis was made within 1 year of the baseline visit) or treated with Androgen Deprivation Therapy for the first time within 1 month prior to the baseline visit, or to be treated with Androgen Deprivation Therapy for the first time within 1 month after the baseline visit
Critètes d'exclusion	Unwilling to provide consent, or Are <45 years of age Patients will be eligible for RADICAL PC1, but will not be eligible for RADICAL PC2 if they: see a cardiologist every year, or are undertaking all of the following: aspirin use, and statin use, and ACE-I use, and exercise 4 or more times per week

Groupe d'étude en oncologie du Québec